Drug Profile
Research programme: metabolic disorders therapy - Metabolex/Takeda
Latest Information Update: 20 Dec 2013
Price :
$50
*
At a glance
- Originator Metabolex; Takeda
- Developer CymaBay Therapeutics; Takeda
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 10 Dec 2013 Discontinued for Metabolic disorders in USA (unspecified route)
- 15 Apr 2010 Early research in Metabolic disorders in USA (unspecified route)